Home
Pharmaceuticals
Brain Related Drug Development
Technology & Pipeline
Lantibiotics
Vaccine Program
Science & Technology
News & Media
Press Releases
In The News
Careers
Presentations
Publications
Abstracts
Investors
Investor Relations
Overview
News / Events
Press Releases
Email Alerts
IR Calendar
Company Info
Profile
Presentations
Management Team
Contacts
FAQ
Financial Info
Financials
Financial Results
Stock Data
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
About
Overview
Management Team
Board of Directors
Scientific Advisors
Contact Us
Careers
Home
News & Media
Publications
News & Media
Press Releases
In The News
Careers
Presentations
Publications
Abstracts
Publications
Pharmacodynamic activity of the lantibiotic MU1140
Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics
Elucidation of the Antimicrobial Mechanism of Mutacin 1140
An Alternative Bactericidal Mechanism of Action for Lantibiotic Peptides That Target Lipid II
Structure and Dynamics of the Lantibiotic Mutacin 1140
Covalent structure of mutacin 1140 and a novel method for the rapid identification of lantibiotics
Genetic and Biochemical Analysis of Mutacin 1140, a Lantibiotic from Streptococcus mutans
Isolation of a Streptococcus mutans Strain Producing a Novel Bacteriocin
« Previous
1
2